RBC Capital Initiates Coverage On Praxis Precision Medicine with Outperform Rating, Announces Price Target of $449

Benzinga Newsdesk www.benzinga.com Positive 80.0%

Neg 0% Neu 0% Pos 80%

RBC Capital analyst Leonid Timashev initiates coverage on Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform rating and announces Price Target of $449.